Nautilus Biotechnology, Inc.·4

Sep 28, 4:01 PM ET

Sankar Subramanian 4

4 · Nautilus Biotechnology, Inc. · Filed Sep 28, 2022

Insider Transaction Report

Form 4
Period: 2022-09-26
Sankar Subramanian
Senior VP, Product Development
Transactions
  • Purchase

    Common Stock

    2022-09-27$2.03/sh+5,000$10,14991,250 total
  • Purchase

    Common Stock

    2022-09-26$2.02/sh+10,000$20,25086,250 total
Footnotes (3)
  • [F1]Represents the weighted average share price of an aggregate total of 10,000 shares purchased in the price range of $2.00 to $2.05 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
  • [F2]Includes 1,250 shares of Common Stock acquired on June 1, 2022 through the Issuer's 2021 Employee Stock Purchase Plan.
  • [F3]Represents the weighted average share price of an aggregate total of 5,000 shares purchased in the price range of $2.02 to $2.04 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

Documents

1 file
  • 4
    wf-form4_166439528878324.xmlPrimary

    FORM 4